Acumen Pharmaceuticals, Inc. ABOS

2.24 0.00 0.00% as of 25 Sep
Market cap
$161.6M
P/E
0.0×
Dec '17 Dec '19 Dec '20 Dec '21 Dec '22 Dec '23 Dec '24 Dec '25
P/E ratio
— 0.00 0.00 — — — — —
P/S ratio
— 6.05 6.05 — — — — —
P/FCF ratio
— 0.00 0.00 — — — — —
P/Operating CF
— (2.04) (2.04) — — — — —
P/B ratio
— 0.00 0.00 — — — — —
Price to Tangible BV
— 0.00 0.00 — — — — —
EV/Sales
— (41.87) (41.87) — — — — —
EV/EBITDA
— 5.43 5.43 — — — — —
EV/Operating CF
— 5.58 5.58 — — — — —
EV/FCF
— 5.58 5.58 — — — — —
Quick Ratio
— 8.60 46.00 37.74 22.73 18.77 6.21 3.89
Current Ratio
— 9.38 46.57 38.60 23.08 19.01 6.46 4.07
Net Debt/EBITDA
— 0.84 5.53 10.00 3.98 3.33 1.20 0.69
Debt/Assets
0.00% 0.00% 0.00% 0.00% 0.05% 9.64% 12.31% 25.37%
Debt/Equity
— 0.00 0.00 0.00 0.00 0.11 0.16 0.44
Asset Turnover
— 0.46 0.06 0.00 0.00 0.00 0.00 0.00
Operating CF/Net income
— 0.89 1.02 0.18 0.82 0.82 0.84 0.95
Capex/Depreciation
— — — (0.25) (0.25) 0.01 0.00 0.14
Interest Coverage
— 0.00 0.00 0.00 0.00 0.00 0.00 0.00
ROE
— 51.22% 48.82% (97.40%) (20.71%) (22.98%) (45.60%) (96.20%)
ROA
— (209.94%) (28.31%) (73.23%) (20.08%) (20.67%) (37.27%) (67.07%)
ROIC
— 0.00% 0.00% (39.55%) (250.76%) (71.63%) (179.60%) 0.00%
Return on Tangible Assets
— (119.85%) (16.85%) (51.98%) (24.82%) (22.40%) (67.90%) (131.54%)
Average Days of Receivables
— 6.45 27.71 — — — — —
Research and Development Expense of Revenue
— 505.36% 556.89% 0.00% 0.00% 0.00% 0.00% 0.00%
Selling, General and Administrative Expense of Revenue
— 54.57% 94.08% 0.00% 0.00% 0.00% 0.00% 0.00%
Intangible Assets out of Total Assets
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Share Based Compensation of Revenue
— 10.25% 10.72% 0.00% 0.00% 0.00% 0.00% 0.00%
Graham Net Nets
— (12.49) (12.49) — — — — —
Graham Number
— 0.00 132.11 — — — — —
Earnings Yield
— (1,065.13%) (1,065.13%) — — — — —
Free Cash Flow Yield
— (124.08%) (124.08%) — — — — —
Revenue per Share
— 3.94 3.43 0.00 0.00 0.00 0.00 0.00
Operating CF per Share
— (15.83) (17.78) (0.90) (0.87) (0.89) (1.44) (1.91)
Capex per Share
— 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Free Cash Flow per Share
— (15.83) (17.78) (0.90) (0.87) (0.89) (1.44) (1.91)
Cash per Share
— 15.21 104.48 9.68 4.37 5.01 2.86 1.93
Shareholders Equity per Share
— (26.51) (44.37) 11.23 4.65 5.49 3.03 1.16
Interest Debt per Share
— 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Book value per Share
— (26.51) (44.37) 11.23 4.65 5.49 3.03 1.16
Free Cash Flow
— (6.82) (7.45) (18.00) (35.31) (43.08) (86.23) (115.63)
Working Capital
— 6.41 43.48 193.51 172.52 233.64 150.70 92.25
Capital Expenditures
— — — (0.04) (0.16) (0.02) (0.02) (0.09)
Net Current Asset Value
— (11.56) (18.59) 193.51 172.52 203.46 121.13 69.85
EV/EBIT
— 5.43 5.43 — — — — —
Capex to Sales
— 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Profit Margin
— (452.92%) (510.10%) 0.00% 0.00% 0.00% 0.00% 0.00%
Price to Operating Income
— 0.00 0.00 — — — — —
Other line items
Depreciation/Fixed assets
— — — 4.42 3.98 (24.07) 0.00 0.00
Cash ROIC
— 140.06% (29.58%) (4.29%) (9.64%) (7.99%) (22.52%) (52.89%)
Accounts Receivable Turnover
— 24.42 20.66 — — — — —
Accounts Payable Turnover
— 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover
— — — 0.00 0.00 — — —
Average Days of Payables
— 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days of Inventory on Hand
— — — 0.00 0.00 — — —
Average Receivables
— 0.07 0.07 — — — — —
Average Payables
— 0.38 0.38 0.81 1.36 1.51 3.51 3.10
Average Assets
— 3.66 25.88 137.38 213.46 253.36 274.56 180.91
Average Common Equity
— (15.01) (15.01) 103.30 206.98 227.87 224.39 126.12

Fold the line items

Columns are period end dates